Group 1 - The core viewpoint of the article is that International Medical (000516) is committed to deepening its collaboration with internationally renowned medical institutions based on its accumulated advantageous resources [1] - The internationalization strategy has always been an important direction in the development plan of International Medical [1] - The establishment of joint venture hospitals needs to align with national policies and the company's business development stage [1]

Core Viewpoint - Xi'an International Medical Investment Co., Ltd. has made significant progress in its operational development in the first half of 2025, focusing on enhancing service quality, optimizing operational efficiency, and expanding its business layout [2][3]. Group 1: Operational Achievements - In the first half of 2025, the company achieved a total outpatient and emergency service volume of 1.3191 million visits, a year-on-year increase of 5.42%, while inpatient service volume decreased by 4.01% to 96,300 visits [3]. - The company reported a revenue of 2,034.31 million yuan, a year-on-year decrease of 15.95%, and a net profit attributable to shareholders of -164.96 million yuan, a reduction in losses by 4.98% [3]. - The net operating cash flow was 592.54 million yuan, reflecting a year-on-year increase of 12.75%, indicating stable medical business collections and good capital turnover [3]. Group 2: Business Development and Innovations - The company established new specialized clinical departments and completed 636 clinical application filings for restricted technologies, along with obtaining 24 national authorized patents [2]. - The company has expanded its service offerings by establishing specialized treatment services such as geriatrics and proton therapy to meet market demand [2]. - The integration of artificial intelligence and the expansion of internet hospital services have improved patient service processes and enhanced operational efficiency [2]. Group 3: Financial Performance of Subsidiaries - Xi'an High-tech Hospital reported an outpatient service volume of 578,700 visits, a year-on-year increase of 3.04%, while inpatient service volume decreased by 6.48% [4]. - Xi'an International Medical Center Hospital had an outpatient service volume of 740,400 visits, a year-on-year increase of 7.37%, but a net profit of -113.21 million yuan, a decrease of 44.63% [4]. Group 4: Future Strategies - The company plans to enhance cost control through bed integration and departmental optimization, as well as increase the use of drugs that meet DRG payment standards [5]. - The focus will be on health management, aesthetic medicine, physical examinations, elderly care, and international cooperation to implement differentiated business strategies [5]. - The company aims to strengthen cost control and efficiency while enhancing medical quality and service experience to build competitive advantages and achieve steady growth [6].

证券之星消息，截至2025年8月27日收盘，国际医学(000516)报收于5.34元，下跌3.09%，换手率 2.39%，成交量52.61万手，成交额2.87亿元。 8月27日的资金流向数据方面，主力资金净流出2377.8万元，占总成交额8.29%，游资资金净流入 1903.09万元，占总成交额6.64%，散户资金净流入474.71万元，占总成交额1.66%。 近5日资金流向一览见下表： | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-27 | 5.34 -3.09% | -2377.80万 | -8.29% | 1903.09万 | 6.64% | 474.71万 | 1.66% | | 2025-08-26 | 5.51 0.00% | -1279.40万 | -8.04% | -101.01万 | -0.63% | 1380.41万 | 8.67% | | 2025-08-25 | 5.51 0.55% | -136 ...

证券代码：000516 证券简称：国际医学 编号：2025-05 随着公司旗下医疗机构对 DRG 支付方式改革的适应性正逐步 增强，住院患者服务量稳定，门诊业务持续扩大。 西安国际医学投资股份有限公司投资者关系活动记录表 | | 特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 业绩说明会 | | 投资者关系活动 | □新闻发布会 路演活动 | | 类别 | 现场参观 | | | 其他_____ | | 参与单位名称及 | 开源证券组织走进国际医学活动投资者 29 位 | | 人员姓名 | | | 时间 | 2025 年 8 月 26 日 14:30-17:00 | | 地点 | 西安国际医学中心医院 | | 上市公司接待人 | 副总裁兼董事会秘书丁震 | | 员姓名 | | | | 公司联合开源证券组织"投资者走进国际医学活动"。投资 | | | 者重点参观西安国际医学中心医院康复治疗中心、康复水疗中 | | | 心、VIP 健康管理中心、产后保健中心等重点特色科室，并介绍 | | | 公司经营发展的简要情况，主要内容如下： | | | 1、2025 年上半年公司经营 ...

格隆汇8月27日｜东海证券研报指出，国际医学2025年H1实现营收20.34亿元（同比-15.95%），收入端 承压的主要原因在于DRG/DIP支付方式改革深化导致住院次均费用下降影响；归母净利润-1.65亿元 （同比减亏4.98%）。分季度看，公司经营环比改善显著，2025年Q2归母净利润-0.59亿元（同比、环比 分别减亏14.68%、44.89%）。门急诊服务总量达131.91万人次，同比增长5.42%；住院服务量9.63万人 次，同比减少4.01%，主要受医保支付结构调整影响所致。公司将重点做好业务结构调整、消费类医疗 布局等措施，同步进行成本管控、提升服务效能，更加适应政策变化，推动降本增效成果显现。公司积 极探索"综合医疗+特色专科"的创新业务模式，在医美整形、康复等特色专科进行布局，核心竞争力不 断增强，盈利能力持续提升。维持"买入"评级。 ...

每经AI快讯，东海证券8月27日发布研报称，给予国际医学（000516.SZ，最新价：5.47元）买入评级。 评级理由主要包括：1）收入短期承压，2025Q2环比改善；2）高新医院：诊疗量保持稳健；3）中心医 院：业务规模稳中有升，质子中心年内有望运营。风险提示：管理运营风险，诊疗规模增长不及预期风 险，医护资源短缺风险等。 每经头条（nbdtoutiao）——能给主人"打电话"的宠物智能手机也来了！宠物产业3000亿元市场大爆 发，行业上市公司"涨"声一片 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 （记者 王晓波） ...

21世纪经济报道记者 凌晨 报道 "随着公司旗下医疗机构对DRG支付方式改革的适应性正逐步增强，住院患者服务量稳定，门诊业务持 续扩大。"日前在国际医学（000516）业绩说明会上，该公司人士表示。 国际医学旗下运营两大单体医院，分别为西安高新医院与西安国际医学中心医院。 上半年，虽然门诊业务持续扩大，但其营收、扣非净利双双下滑。其中营收20.34亿元，同比下降 15.95%；扣非净利-1.89亿元，同比下降36.09%。 上述亏损并非孤例。自2018年以来，该公司扣非净利润连续七年为负。 为扭转困局，国际医学不断尝试新业务。业绩说明会现场，该公司人士表示，上半年，国际医学中心医 院设立惠宾科，提供高端定制健康服务，并开设老年护理院，目前开放床位100张。 只是，从最新财务数据来看，新业务并未带动盈利改善，业绩压力依然严峻。 净利下滑 作为国际医学旗下最受瞩目的主力资产，2019年开诊的西安国际医学中心医院自建设之初就承载着集团 极大的期望。 这座总建筑面积达96万平方米的医疗巨舰，规模甚至超过北京协和医院，一度被誉为"全国最大单体医 院"，并定位为集医疗、科研、教学、预防、保健、康复与健康管理于一体的超大型 ...

Group 1 - The core point of the news is that International Medical has experienced a net sell-off in financing activities, with a total financing buy amount of 0.17 billion yuan on August 25, ranking 1954th in the market [1] - Over the last three trading days, from August 21 to August 25, International Medical received financing buy amounts of 0.16 billion yuan, 0.22 billion yuan, and 0.17 billion yuan respectively [1] - On the same day, there were no shares sold or net sold in the securities lending market for International Medical [2]

截至2025年8月25日收盘，国际医学股价报5.51元，较前一交易日上涨0.55%，成交额2.54亿元，换手率 2.10%。 国际医学主营业务为医疗服务，旗下医院覆盖综合医疗、专科诊疗等领域。公司近年来通过学科建设与 科研创新推动业务发展。 风险提示：市场有风险，投资需谨慎。 消息面上，国际医学于8月22日接待了天风证券等多家机构调研，公司高管介绍了2025年上半年经营情 况，包括学科建设、业务布局优化等进展。近一年来，公司累计接受235家机构315次调研。 资金方面，8月25日主力资金净流出1368.75万元，近五日累计净流出663.41万元。 ...

Core Viewpoint - The performance briefing held by Xi'an International Medical Investment Co., Ltd. on August 22, 2025, highlighted the company's operational developments and financial performance for the first half of 2025, with a focus on service expansion, cost control, and strategic adjustments in response to market conditions [1]. Group 1: Operational Developments - In the first half of 2025, the company established one provincial-level clinical key specialty project and completed 636 clinical application filings for restricted technologies, along with obtaining 24 national patents and initiating 13 clinical trial projects for drugs and medical devices, indicating an expansion in academic influence [2]. - The company launched a high-end specialty service in the newly established International Medical Center Hospital and opened a 100-bed elderly care facility to address aging population needs [2]. - The company enhanced patient service experiences and smart healthcare capabilities, optimizing the entire patient service process and expanding internet hospital services [2]. Group 2: Financial Performance - In the first half of 2025, the total outpatient and emergency service volume reached 1.3191 million visits, a year-on-year increase of 5.42%, while inpatient service volume decreased by 4.01% to 96,300 visits [3]. - The company reported operating revenue of 2.0343 billion yuan, a year-on-year decrease of 15.95%, and a net profit attributable to shareholders of -164.96 million yuan, a reduction in losses by 4.98% [3]. - Operating cash flow net amount was 592.54 million yuan, an increase of 12.75% compared to the same period last year [3]. Group 3: Specific Hospital Performance - Xi'an Gaoxin Hospital recorded an outpatient and emergency service volume of 578,700 visits, with operating revenue of 638.74 million yuan, a year-on-year decrease of 17.30%, and a net profit of 30.98 million yuan, down 37.48% [4]. - Xi'an International Medical Center Hospital had an outpatient and emergency service volume of 740,500 visits, a year-on-year increase of 7.37%, but inpatient service volume decreased by 2.80% to 66,000 visits, with operating revenue of 1.3833 billion yuan, down 15.37%, and a net profit of -113.21 million yuan, a decrease of 44.63% [4]. - The company implemented cost control measures, including bed integration and department optimization, and saw an increase in the proportion of out-of-town patients, reaching 35% for Xi'an Gaoxin Hospital and 42% for Xi'an International Medical Center Hospital [4].